News & Updates

A retrospective review of medical records show that paediatric patients with alopecia areata (AA) in Singapore respond well to currently available treatments.

Treatment with tildrakizumab in patients with moderate-to-severe scalp psoriasis helps reduce scalp itch and improve quality of life when compared with placebo, with no new safety signals, as shown in a phase IIIb study.

Dietary sodium intake, measured through 24-hour urinary sodium excretion, is positively associated with atopic dermatitis (AD), as suggested in a study.

Use of neoadjuvant daromun in addition to surgery is safe and provides survival benefits in patients with resectable, locally advanced melanoma, results of the PIVOTAL study have shown.

Treatment with dupilumab substantially improves symptoms, quality of life, and other outcomes in patients with atopic hand and foot dermatitis (H/F AD), with an acceptable safety profile, results of a study have shown.